Close this search box.

Patent Granted to IGC Pharma For Groundbreaking Drug To Treat Agitation in Alzheimer’s

The company anticipates this milestone to facilitate approvals in other countries including the U.S. and Europe.

The Formulation, targeting agitation in Alzheimer's

Potomac, MD, February 23, 2024
​-IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendiant) has issued an analyst coverage research report on the Company’s common stock.
A copy of the analyst report can be obtained directly from Ascendiant:

What we do is essential, adressing an unmet need

Agitation is more than physical/verbal aggression.
It is distressingly common in Alzheimer’s, and leads to hospitalizations, increased medications, and higher mortality rates. Our solution has the potential to alleviate agitation, prolong the time families can spend together, and significantly reduce caregiver burden. With minimal side effects and no black box warnings the impact of our investigational drug is enormous.

Alzheimer's Desease

Alzheimer’s affects over 400 million individuals across its continuum, making it the leading cause of dementia worldwide. With no cure, it affects as many as 22% of all persons aged 50 and above. It is likely that you or someone you know has been touched by this devastating disease. I invite you to join us in the fight against Alzheimer’s. Together we can make a difference.

Recent Post

Follow Us

Related Posts